IJARR - Menu
- About IJARR
- Publication Ethics
- Call For Paper
- Editorial Board
- Guide to Authors
- Submit Manuscript
- Table of Contents
Search Authors Articles
- *1Birhanu Hailu on Google Scholar
- *1Birhanu Hailu on Pubmed
- 2Berihu Gebrekidan on Google Scholar
- 2Berihu Gebrekidan on Pubmed
- 1Gezahign Alemayehu on Google Scholar
- 1Gezahign Alemayehu on Pubmed
- 3Teshale Teklu on Google Scholar
- 3Teshale Teklu on Pubmed
Preferences
Article Statistics
Viewing Options: View Full Article - PDF Download Full Article - PDF
Effects of buserelin acetate Treatment 12 days Post Inseminations in improvement of Conception Rate in Repeat Breeding Dairy Cattle in Mekelle, Tigray, Ethiopia
*1Birhanu Hailu, 2Berihu Gebrekidan, 1Gezahign Alemayehu and 3Teshale Teklu
Abstract
Accepted 23rd March, 2015
The aim of the present study was to evaluate the effect buserelin acetate given 12 days post AI and double inseminations during estrous period of dairy cattle and improvement of conception rate. Field trial was carried out on repeat breeding cross breed dairy cows which are lactating and apparently healthy that exhibits estrus regularly. A total of forty four repeat-breeding cows from twenty herds were selected and assigned randomly in to two equal groups, A and B: one treated and one control group. Group A (n=22) cattle were treated intramuscularly with 10 µg buserelin acetate 12 days post AI. GroupB (n=22) cattle were inseminated once during estrus exhibition with single service and considered as control. Dairy cows were examined for pregnancy after three months through rectal palpation. Pregnancy rates recorded were 55%, and 32% in A and B respectively. The conception rates of treated group exceed control group by 23% respectively. Treated group showed a significant statistical variation (P<0.05) as compared to control groups. From this experiment it is recommended that the use of GnRH injection 12 days post AI and can improve pregnancy rate in repeat breeding cross breed dairy cows.
Keywords: Crossbred cattle, Estrus, buserelin acetate, Pregnancy rates, treated group